PreprintPDF Available

The Post Orgasmic Illness Syndrome (POIS) Selective Bibliography

Authors:
Preprints and early-stage research may not have been peer reviewed yet.

Abstract

POST COITAL ALLERGY - A CASE REPORT OF POST ORGASMIC ILLNESS SYNDROME (POIS) (Abstract) Post-orgasmic illness syndrome (POIS) is a rare but debilitating cluster of symptoms occurring after ejaculation and affecting especially men. POIS starts with flu-like symptoms, such as feverishness or sweating, brain fog, muscle pain, heavy legs followed by concentration and attention difficulties and irritation. Complaints last for about 5 to 7 days, after which they disappear spontaneously after 3 to 7 days, until the next ejaculation. Diagnosis is difficult and consists in several clinical criteria, a functional test and allergy assessment. Keywords: SEMINAL PLASMA PROTEIN ALLERGY(SPPA), POST ORGASMIC ILLNESS, SEXUAL DISTRESS
Med. Surg. J. Rev. Med. Chir. Soc. Med. Nat., Iaşi 2019 vol. 123, no. 2
INTERNAL MEDICINE - PEDIATRICS CASE REPORTS
258
POST COITAL ALLERGY A CASE REPORT OF POST ORGASMIC
ILLNESS SYNDROME
Celina Silvia Stafie*, Ingrid Ioana Stafie
“Grigore T. Popa” University of Medicine and Pharmacy Iasi
Faculty of Medicine
Department of Preventive Medicine and Interdisciplinary
*Corresponding author. E-mail: cstafie@hotmail.com
POST COITAL ALLERGY-A CASE REPORT OF POST ORGASMIC ILLNESS SYN-
DROME (Abstract) The post-orgasmic illness syndrome (POIS) is a rare, but debilitating
cluster of symptoms, occurring after ejaculation. The clinical case presented is a male p a-
tient, his complains started after ejaculation, four years ago, with flu-like symptoms, fever-
ishness and sweating, brain fog, muscle pain and heavy legs, followed by concentration and
attention difficulties and irritation. This status last for about 5 to 7 days, disappear spontan e-
ously after 3 days and reappear after the next ejaculation. This postcoital illness was worse n-
ing during the years. The clinical assessment and differentiation of the diagnosis was diffi-
cult and consisted in several clinical criteria, a functional test and allergy valuation. The
combination of symptoms and pathophysiological mechanisms pointed to other sex related
allergies, such as seminal plasma protein allergy. Keywords: SEMINAL PLASMA PRO-
TEIN ALLERGY, POST ORGASMIC ILLNESS, SEXUAL DISTRESS.
The only universal in human sexuality is
variability itself (1). During the last 5 years
we have diagnosed and treated three differ-
ent cases of sex allergy: latex allergy, semi-
nal plasma allergy and, the most recent, post
orgasmic illness syndrome (POIS). Sex and
intimate contacts can represent a risk factor
for allergic reactions, because they may
favor direct contact with sensitizing sub-
stances(1).
Pathogenesis of POIS might include type
2 immune allergic reactions, but it does not
necessary involve atopy (2). The mean se-
rum total IgE in the non-atopic males was
27 kU/L (range 6-78 kU/L), indicating that
in these men this immunological marker was
normal (2).
Pathophysiology of POIS shows an im-
munological process which explains the
systemic reaction of the body and not only a
local genital reaction, since only the immune
system is capable of inducing very rapid and
serious physical and mental symptoms (3).
The support for an immunological cause of
these flu-like complaints was found in re-
ports on cytokines inducing a flu-like state
(4, 5). There are two types of POIS, a prima-
ry type in which POIS is manifest from the
first ejaculations in puberty or adolescence
and a secondary type, in which POIS starts
later in life (2, 6).
CASE REPORT
We present the case of a 34-year-old
male patient, with a very demanding job,
married young, heterosexual, with two
healthy children. He had no intimate rela-
tionships with other women after getting
Post coital allergy a case report of post orgasmic illness syndrome
259
married.
The patient had two appointments at our
clinic during the last 4 years, the first in
2014 and the second in 2017. He initially
presented for a “strong dysphoric status after
intercourse”, during the last months before
his visit, “aggravating each time, from ab-
dominal pain and nausea to generalized
sickness”, to which obnubilation, confusion
and severe migraine were added.
The particularity of the case is that the
patient had no obvious local or generalized
allergic reaction, which can delay and even
obscure the diagnosis. Previously he had
consulted other doctors, urologists and in-
ternists, but the allergist was his last chance
to have this mysterious disease diagnosed
and treated.
Chief complaint: generalized post coi-
tal/post orgasmic illness over the last 4
years.
Past medical history: no history of aller-
gy, high blood pressure (145/90 mm Hg),
endoscopically diagnosed gastric ulcer,
history of recurrent low urinary tract infec-
tions. The patient was asymptomatic at both
consultations.
Family history: one of his children was
diagnosed with atopic dermatitis. No family
history of allergies or diabetes.
Current medication: occasionally, seda-
tives; he was using latex free condoms, with
no influence on symptoms.
Self-observation and self-intervention:
He was hiding the truth from his wife, refus-
ing to deal with the problem as a couple. He
noticed that when he interrupted intercourse
before reaching orgasm, symptoms did not
appear.
Physical exam: absence of physical
signs or symptoms, no local or generalized
eruption or swelling, normal blood pressure
and pulse.
Lab tests showed a total IgE = 12 UI/L;
seminal-fluid specific IgE = 45kUI/L (nor-
mal range < 0.35 kUI/L); CIC (Circulating
Immune Complexes) = 45; serum comple-
ment = 570 UI; (++)presence of cryoglobu-
lins
Skin prick test with his own semen re-
sulted in a 14 mm wheal and erythema (+1),
while patch test with his own semen was
refused, as well as diamine oxidase (DAO)
determination and the skin biopsy for mas-
tocytosis.
Functional Diagnosis 1. A non-specific
clinical test of POIS - advise the patient to
stop masturbating or intercourse just before
the first genital sensations of an impending
ejaculation occur while having a full erec-
tion (2-17). 2. Difficult but clarifying: this is
not easy to perform as one asks the patient
to stop his sexual activity while having an
increasing pleasure in this activity. POIS
symptoms will not become manifest after
this non-specific clinical diagnostic test.
Clinical diagnosis The five criteria of
POIS are as follows: 1: One or more of the
following symptoms: sensation of a flu-like
state, extreme fatigue or exhaustion, muscle
weakness, feverishness or sweating, mood
disturbances and/or irritability, memory
difficulties, concentration problems, inco-
herent speech, congested or runny watery
nose, itchy eyes; 2: All symptoms occur
immediately (e.g., seconds), soon (e.g.,
minutes), or within a few hours after ejacu-
lation that is initiated by coitus, and/or mas-
turbation, and/or spontaneously (e.g., during
sleep); 3: Symptoms occur always or nearly
always in more than 90% of ejaculation
events; 4: Most of these symptoms last for
about 2 to 7 days; 5: The symptoms disap-
pear spontaneously.
Allergy diagnosis Skin prick test with
autologous semen: the purpose was to ob-
jectify the skin reaction after inoculation of
the semen using a protocolized intracuta-
neous (IC) skin-prick test. It was performed
with the male’s own semen (autologous
Celina Silvia Stafie, Ingrid Ioana Stafie
260
semen) and compared with a placebo skin
reaction with IC saline 0.9% (6). The pa-
tient masturbated at home to produce se-
men. In hospital the harvested semen sam-
ple was defrosted and diluted with saline
0.9% to a concentration of 1:40,000. In
addition, 0.05 mL of each dilution was IC
injected at the volar side of the left fore-
arm. The skin reaction to autologous semen
and placebo were interpreted at 15 minutes
after IC injections and found to be positive
when the diameter of the wheal was > 5
mm with local erythema (6). The grading
system of the skin reactions was as follows:
I. wheal and erythema < 5 mm = negative;
II. wheal 5-10 mm and erythema of 11-20
mm = 1+; III. wheal erythema of 21-30 mm
= 2+; IV. erythema of 31-40 mm = 3+; and
V. wheal > 15 mm or erythema of > 40 mm
= 4+ (2, 6).
Positive Diagnosis Based on the func-
tional (positive non ejaculatory test), allergy
(+1 level) and clinical diagnosis (all 5 crite-
ria were met), we made the following posi-
tive diagnosis, as being the most likely: 1.
Post orgasmic illness syndrome type II (late
onset) 2. Seminal Plasma Protein Allergy
(SPPA) (autoimmune)
Differential diagnosis that can explain
at least partially the clusters of symptoms
included: 1.Seminal Plasma Protein Allergy
(SPPA); 2. Systemic Mastocytosis; 3.
Drug/Substance abuse; 4. Autoimmune
disease with involvement of sexual activi-
ty; Unknown syndrome linked to sexual
activity (other Rare forms of Post-coital
Sickness).
Treatment consisted in desensitization
with autologous semen. Since the patient
score was +1 (wheal and erythema +14
mm), the treatment was postponed until the
patient should accept a patch test and di-
amono oxidase (DAO) determination. All
treatments should be performed in hospital
and attentively surveyed by the allergist and
emergency care intervention, if needed.
Desensitization is made with extremely
diluted autologous semen (1/40,000), by
gradually higher concentrations of autolo-
gous semen. Titration are to be performed
according to local skin reactions post inocu-
lation, aiming at a wheal and flare response
of 3+. This score has to be maintained for a
period of at least 2 years.
DISCUSSION
Clinical data from urology and androlo-
gy reported the post-orgasmic disease status
at the beginning of 2000, especially in males
and after ejaculation. There are only 50
cases around the world. From the three dif-
ferent cases of sexual allergy, latex allergy,
seminal plasma allergy and post -orgasmic
disease, the latter most challenged, because
there is no objective local allergic reaction
and all the symptoms are subjectively pre-
sented by the patient, not obvious to the
physician. The only support is the patient's
observation of the inventory and timing of
clinical symptoms.
In this case, we benefited from a very pa-
tient and self-aware patient who self-
intervening if he had given consistent help
because he performed the functional test,
stopped sexual intercourse before the first
genital sensations of an imminent ejacula-
tion, complete erection. The test was posi-
tive and gave us the certainty that the aller-
gic reaction is due to autoimmune allergies
to its own seminal fluid.
The first differential diagnosis was a co-
existing one, because of the high specific
IgE to his own seminal plasma protein, a
range of 0-0.35kUI/L being the normal val-
ues accepted for absence of SSPA. Thus, the
patient has a high degree of autoimmunity to
his own seminal plasma protein. We can
affirm that POIS include SSPA.
The second differential diagnosis was
invalidated, because of the absence of ma-
Post coital allergy a case report of post orgasmic illness syndrome
261
jor and/or minor criteria for mastocytosis.
There were no obvious rashes or hemato-
logical changes in the number or morphol-
ogy of mast cells. Also, there are no con-
sistent data supporting the third differential
diagnosis, as there was no history or clini-
cal evidence of drug or other substance use,
although clinical status was suggestive of
intoxication. It is also important to estab-
lish any influence on males with POIS, of
the 25-OH D vitamin deficiency, if we
consider the epidemic character and the
implications of this vitamin (7). Is it the
semen or the seminal fluid? The question is
which part of the ejaculate contains the
antigen (Ag) that triggers the immunologi-
cal reaction? Waldinger (3, 4, 5) reported
the occurrence of POIS before and after
sterilization in three men. This phenome-
non means that the Ag is most likely not
bound to the spermatozoa but associated
with the seminal fluid. After sterilization,
spermatozoa are no longer released into the
genital system, but seminal fluid continues
to be produced, for example by the prostate
and/or the seminal vesicles.
CONCLUSIONS
We have presented an allergy case with a
certain immunotherapy status, that is not
associated with elevated serum total IgE or
urticaria but may be associated with an auto-
immune reaction in the plasma protein in the
fluid seed.
Indirect clinical evidence suggests that
the Ag triggering the POIS systemic reac-
tion is not bound to spermatozoa, but to
seminal the fluid produced by prostate tis-
sue.
The crucial benefit of the case is to point
out the importance of self-observation and
self-intervention of the patient with POIS,
for there is no possible diagnosis of this rare
disease, without the contribution of the pa-
tient, since all symptoms are invalidating
and restricting the visit to a doctor and the
possibility of an onsite immediate allergolo-
gy evaluation.
REFERENCES
1. Kinsey A. Sexual Report in Human Male, Indiana University Press, 1948
2. Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf
1995; 13: 371-406.
3. Waldinger MD, Schweitzer DH. Post orgasmic illness syndrome: two cases. J Sex Marital Ther 2002;
28: 251-256.
4. Waldinger MD, Meinardi MM, Zwinderman AH, et al. Post orgasmic Illness Syndrome (POIS) in 45
Dutch Caucasian males: clinical characteristics and evidence for an immunologic pathogenesis (Part
1). J Sex Med 2011; 8: 1164-1170.
5. Waldinger MD, Meinardi MM, Schweitzer DH. Desensitization therapy with autologous semen in
two Dutch Caucasian males: beneficial effects in Post orgasmic Illness Syndrome (POIS; Part 2). J
Sex Med 2011; 8: 1171-1176.
6. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995; 105: 31-
57.
7. Barzoi RO, Rezus E, Petrariu FD, Badescu C, Ciocoiu M. Implications of vitamin D deficiency in
inflammation due to rheumatoid arthritis. Rev. Med. Chir. Soc. Med. Nat. Iasi 2018; 122(4); 676-681.
ResearchGate has not been able to resolve any citations for this publication.
Article
A large body of clinical experience on the adverse consequences of cytokine administration has accumulated since the last decade. Side-effects reported after the therapeutic use of cytokines has provided evidence that activation of the immune response may sometimes have deleterious consequences. Several effects appeared as a direct consequence of the immune activation induced by cytokines e.g. flu-like reactions, vascular leak syndrome. Cytokine-induced exacerbation of underlying diseases or immune dysregulation were other complications of growing concern. Interferon-alpha (IFN-α) treatment has now been clearly linked with the exacerbation or the occurrence of several types of autoantibodies or autoimmune diseases (thyroiditis, systemic lupus erythematosus, hematologic disorders, insulin-dependent diabetes mellitus) or diseases involving altered cell-mediated immune functions (inflammatory dermatologic diseases, nephritis, pneumonitis, colitis). By contrast immunological side-effects of IFN-β and IFN-γ have been seldom reported. However, the extent of clinical experience with both of these cytokines is still very limited. Interleukin-2 (IL-2) has also been implicated in various conditions that may involve immunopathological processes (thyroid disorders, rheumatoid arthritis, dermatological diseases, interstitial nephritis). Growth factors have been more specifically linked with the development or the exacerbation of dermatological inflammatory diseases through neutrophils, monocytes/macrophages or eosinophils activation (e.g. cutaneous vasculitis and generalized cutaneous eruption, Sweet's syndrome, bullous eruption, psoriasis). Exacerbation of autoimmune thyroiditis was described with granulocyte-macrophage colony-stimulating factor (GM-CSF) only. The immunogenicity of cytokines is also of great relevance and the occurrence of antibodies binding IFN-α and IFN-β, IL2 and GM-CSF have been reported. While the clinical significance of non-neutralizing antibodies is not clearly established, an absence of response or reversal of clinical efficacy has been described in patients developing neutralizing antibodies. Finally, several isolated reports have recently suggested that IFN-α treatment may be associated with several immunosuppressive effects while IL-2 is clinically associated with an increased incidence of infectious complications.
Article
Postorgasmic illness syndrome (POIS) is a post-ejaculatory complex of local and/or systemic symptoms that nearly always occurs within seconds, minutes, or hours post-masturbation, coitus, or spontaneous ejaculation. Recent data suggest an autoimmunogenic/allergic underlying mechanism. To treat males with POIS by hyposensitization with their own semen (autologous semen). Two males suffering from POIS, of which one male with coincidental lifelong premature ejaculation (PE) were investigated. Based on their local and systemic symptoms including a positive dermatologic reaction after skin-prick testing with autologous semen, auto-allergy to semen was likely an underlying mechanism. A hyposensitization program was initiated, including multiple subcutaneous (SC) injections with autologous semen, initially at 2 weeks intervals in the first year and gradually at 4 weeks intervals in the second and third year. From initial semen dilutions of 1 on 40,000 and 1 on 20,000, the titers were gradually increased to 1 on 20 and 1 to 280, respectively. Evaluation with a dedicated questionnaire about severity of POIS symptoms and specialized interviews on self-perceived intravaginal ejaculation latency times (IELT) before and during the desensitization program. POIS was confirmed in both subjects, PE was confirmed in one male, and skin-prick tests with autologous semen in both subjects were positive. During the program, gradual reduction of complaints resulted in 60% and 90% amelioration of POIS complaints at 31 and 15 months, respectively, which coincided in one male with a delay of the IELT from 20 seconds at baseline to 10 minutes after 3 years of treatment. The cause of this association with IELT is unknown and remains to be elucidated. Two males with POIS were successfully treated by hyposensitization with autologous semen, which supports an immunogenic/allergic etiology and underscores the clinical implication for immunological sexual medicine.
Article
Postorgasmic illness syndrome (POIS) is a combination of local allergic symptoms and transient flu-like illness. In this study, the investigators propose five preliminary criteria to establish the diagnosis. To describe the clinical details in 45 males being suspected of having POIS and to test an immunogenic hypothesis as the underlying mechanism of their presentations. Forty-five males were studied according to standardized protocol, including neuropsychiatric and medical sexological evaluations; their complaints were categorized using their own words, and their self-perceived intravaginal ejaculation latency time (IELT). Skin-prick testing with autologous diluted semen in 33 men were also performed. Clinical features of POIS including self-perceived IELTs and the results of skin-prick testing with autologous diluted seminal fluid. Of the 45 included men, 33 subjects consented with skin-prick testing. Of them, 29 (88%) men had a positive skin-prick test with their own (autologous) semen, and four had a negative test. In 87% of men, POIS symptoms started within 30 minutes after ejaculation. Complaints of POIS were categorized in seven clusters of symptoms, e.g., general, flu-like, head, eyes, nose, throat, and muscles. Local allergic reactions of eyes and nose were reported in 44% and 33% of subjects, a flu-like syndrome in 78% of subjects, exhaustion and concentration difficulties in 80% and 87% of subjects. Of all subjects, 58% had an atopic constitution. Lifelong premature ejaculation, defined as self-perceived IELT < 1 minute, was reported in 25 (56%) of subjects. The combination of allergic and systemic flu-like reactions post-ejaculation together with a positive skin-prick test in the majority of males underscores the hypothesis of an "immunogenic" etiology of POIS, e.g., that POIS is caused by Type-1 and Type-IV allergy to the males' own semen, as soon it is triggered by ejaculation.
Article
A number of cytokines are used as haemopoietic growth factors and this review focuses on toxicities associated with granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-1, IL-3, IL-4, IL-6 and macrophage colony-stimulating factor (M-CSF). Both GM-CSF and G-CSF, currently approved for clinical use, are generally well tolerated by the majority of patients during short term administration. Constitutional symptoms and bone pain are the most frequently reported adverse effects, but they are rarely treatment-limiting. Reactivation of rheumatoid symptoms, and exacerbation of autoimmune thyroiditis or autoimmune haematological disorders have sometimes been described. Severe cardiovascular complications include the possibility for arterial thromboses and the vascular leak syndrome, which is more specifically observed with GM-CSF. Reports of several cases and small series of patients have suggested that growth factors might increase the pulmonary toxicity of chemotherapy, a possibility that remains debated and requires further attention. Generalised or local cutaneous reactions are frequently noted with GM-CSF. Leukocytoclastic vasculitis was observed with both growth factors, while neutrophilic dermatoses have been mostly described with G-CSF. Exacerbation of psoriasis and isolated anaphylactic reactions have appeared with GM-CSF and G-CSF. The hepatotoxic potential of the growth factors is not clearly established, but the occurrence of coagulation abnormalities has recently been reported. Renal and biological disturbances are usually transient. Long term treatment with GM-CSF and G-CSF also seems to be well tolerated, but the possible occurrence of several adverse events, i.e. bone disorders, leukaemia, unmasking or acceleration of underlying disease, require further investigation in patients receiving prolonged treatment, as in myelodysplasia. Finally, antibodies against growth factors have been reported only with GM-CSF. Other cytokines are still under investigation. Flu-like and constitutional symptoms, sometimes dose-limiting, have been reported with IL-1, IL-3, IL-4 and IL-6, while M-CSF was occasionally associated with such adverse effects. More specific adverse events, also frequently considered as dose-limiting toxicities, include hypotension with IL-1, severe headache or skin rash with IL-3, and nasal congestion and gastroduodenal lesions with IL-4. Severe capillary leak syndrome has been reported only with IL-4. M-CSF toxicity is minimal and limited to reversible but sometimes dose-limiting thrombocytopenia and ophthalmological symptoms with the recombinant product. Again, the safety of long term administration of these cytokines has not yet been determined, and IL-3-induced disease progression in myelodysplastic patients has been suggested.
Article
We describe the symptoms of a postejaculatory syndrome in two men with spontaneous ejaculations. The syndrome consists of severe fatigue, intense warmth, and a flulike state, with generalized myalgia. These symptoms occur rapidly after ejaculation and only disappear after 4 to 7 days. The symptoms are so severe that sexual activity is avoided. The cluster of symptoms is named postorgasmic illness syndrome (POIS). To date, no explanation has been offered for the etiology and pathogenesis of the symptoms, and the prevalence is unknown. Both cases are presented to draw attention to this syndrome for further research regarding etiology, pathogenesis, and treatment.
Dutch Caucasian males: clinical characteristics and evidence for an immunologic pathogenesis (Part 1)
Dutch Caucasian males: clinical characteristics and evidence for an immunologic pathogenesis (Part 1). J Sex Med 2011; 8: 1164-1170.
Implications of vitamin D deficiency in inflammation due to rheumatoid arthritis
  • R O Barzoi
  • E Rezus
  • F D Petrariu
  • C Badescu
  • M Ciocoiu
Barzoi RO, Rezus E, Petrariu FD, Badescu C, Ciocoiu M. Implications of vitamin D deficiency in inflammation due to rheumatoid arthritis. Rev. Med. Chir. Soc. Med. Nat. Iasi 2018; 122(4); 676-681.